RESEARCH PROFILE
MOTS-c
Mitochondria-Derived Peptide • Metabolic & Cellular Stress Research
MOTS-c is a 16 amino acid peptide encoded within mitochondrial DNA rather than the nuclear genome. Research has focused on cellular energy regulation, metabolic stress, AMPK signaling, glucose handling, exercise adaptation, and mitochondria-to-nucleus communication.
Most mechanistic evidence remains preclinical, while direct human evidence for native MOTS-c is limited.
INVESTIGATIONAL • NOT FDA APPROVED • PRIMARILY PRECLINICAL EVIDENCE
MOTS-c AT A GLANCE
Category
Mitochondria-derived peptide
Full Name
Mitochondrial open reading frame of the 12S rRNA-c
Structure
16 amino acid peptide
Primary Research Focus
AMPK • Glucose metabolism • Exercise adaptation • Cellular stress signaling
Evidence Base
Strongest in animal and laboratory research
Human Evidence
Limited observational and mechanistic human data
Regulatory Status
Not FDA approved
IMPORTANT DISTINCTION
MOTS-c is unusual because it is encoded by mitochondrial DNA rather than by nuclear DNA.
That places it within a small family of mitochondria-derived peptides involved in communication between mitochondria and the rest of the cell.
Your Project source identifies MOTS-c primarily as a metabolic signaling peptide, not simply as an energy stimulant.
Research interest centers on how cells adapt to metabolic stress, exercise, glucose demand, and aging-related changes in mitochondrial signaling.
WHAT IS MOTS-c?
MOTS-c is a naturally occurring 16 amino acid mitochondrial-derived peptide.
It is encoded within the mitochondrial 12S rRNA region.
Unlike most proteins and peptides, which are encoded by genes located in the cell nucleus, MOTS-c originates from the mitochondrial genome.
Researchers first identified MOTS-c in the context of metabolic homeostasis.
Subsequent work has examined its role in:
Glucose metabolism
Insulin sensitivity
Cellular energy sensing
Exercise adaptation
Mitochondrial stress response
Nuclear gene signaling
Aging biology
Bone metabolism
Inflammatory pathways
One of the distinctive features of MOTS-c research is its proposed ability to function as a mitochondria-to-nucleus signaling molecule.
Under cellular stress, MOTS-c has been reported in preclinical models to move into the nucleus and influence gene-expression programs associated with metabolism and stress adaptation.
MECHANISM OF ACTION
The best-characterized MOTS-c mechanisms involve energy sensing and cellular stress-response pathways.
AMPK ACTIVATION
One of the central pathways associated with MOTS-c is AMP-activated protein kinase, or AMPK.
AMPK acts as a cellular energy sensor.
When cellular energy availability falls, AMPK helps shift metabolism toward pathways that conserve or generate energy.
Preclinical MOTS-c research has reported activation of AMPK.
FOLATE & PURINE METABOLISM
Your Project source describes MOTS-c as influencing folate and purine pathways in a manner that contributes to accumulation of AICAR, an endogenous AMPK-activating metabolite.
This provides one proposed mechanism linking MOTS-c to AMPK signaling.
GLUCOSE HANDLING
Preclinical studies suggest MOTS-c can influence glucose uptake and insulin-related metabolism.
Research has reported effects involving GLUT4 translocation, which helps skeletal-muscle cells move glucose transporters to the cell surface.
These findings are relevant to metabolic research but remain largely preclinical.
MITOCHONDRIA-TO-NUCLEUS SIGNALING
MOTS-c has also been reported to translocate to the nucleus during cellular stress.
There, it may interact with transcriptional programs involved in:
Metabolic adaptation
Oxidative stress
Cell survival
Energy homeostasis
NRF2 & STRESS RESPONSE
Your Project source also discusses the NRF2 pathway, which regulates antioxidant and cellular-defense genes.
MOTS-c research has explored potential effects on antioxidant-response signaling.
EXERCISE RESPONSE
MOTS-c levels appear to respond to exercise in some human and animal research.
This has contributed to interest in whether the peptide participates in exercise-induced metabolic adaptation.
IMPORTANT MECHANISM LIMITATION
Mechanistic activity does not equal demonstrated clinical benefit.
AMPK activation, GLUT4 signaling, and mitochondrial stress adaptation provide biological rationale for continued research, but they do not establish MOTS-c as an effective treatment for diabetes, obesity, aging, fatigue, or athletic performance.
WHAT THE RESEARCH SHOWS
PRECLINICAL METABOLIC RESEARCH
The strongest MOTS-c evidence comes from animal and laboratory studies.
A landmark 2015 study reported that MOTS-c improved metabolic homeostasis in mice and reduced diet-induced obesity and insulin resistance.
These findings established much of the modern research interest in MOTS-c.
EXERCISE & PHYSICAL PERFORMANCE
Animal studies have also investigated MOTS-c in exercise-related contexts.
Research cited in the Project profile reported improved physical capacity in mice, including older animals, with effects involving skeletal-muscle metabolism and exercise adaptation.
These findings are preclinical.
AGE-RELATED BIOLOGY
Research has examined age-related declines in endogenous MOTS-c levels.
Animal studies have explored whether exogenous MOTS-c can influence age-associated metabolic decline and physical capacity.
This has led to considerable longevity-related interest.
However, anti-aging or lifespan extension has not been established in humans.
HUMAN OBSERVATIONAL EVIDENCE
Your Project source identifies limited human research examining circulating MOTS-c.
One observational study reported that higher serum MOTS-c levels correlated with greater lower-body muscle strength in healthy adults.
This is an association, not evidence that administering MOTS-c increases strength.
EXERCISE-INDUCED MOTS-c
Human research has also examined endogenous MOTS-c responses to physical activity.
Some studies suggest circulating MOTS-c may change following exercise.
This supports a possible role in exercise physiology but does not establish the effects of exogenous MOTS-c administration.
CB4211 ANALOG RESEARCH
Your Project profile discusses CB4211, a synthetic MOTS-c analog that entered Phase I clinical development.
The Project source notes that CB4211 was reported as generally well tolerated in early clinical testing.
However:
CB4211 is related to MOTS-c but is not identical to native MOTS-c.
Safety data from CB4211 should therefore not be presented as direct clinical safety evidence for native MOTS-c.
BONE & INFLAMMATORY RESEARCH
Preclinical studies have also investigated MOTS-c in:
Bone metabolism
Inflammatory signaling
Pain models
Cellular stress responses
These remain early-stage research areas.
IMPORTANT EVIDENCE LIMITATION
The dedicated clinical-evidence section of the Project source states that no published human randomized controlled trial has tested native MOTS-c for a clinical endpoint.
Therefore, human claims involving:
Improved insulin sensitivity
Weight loss
Exercise performance
Body composition
Longevity
Anti-aging
Recovery
remain unproven for exogenous native MOTS-c.
SAFETY & RESEARCH CONSIDERATIONS
Native MOTS-c does not have a large human safety database.
Most safety discussions rely on animal work, community observations, and related-compound research.
REPORTED COMMUNITY EFFECTS
Your Project profile identifies reported effects such as:
Injection-site redness or swelling
Flushing or skin warmth
Headache
Mild fatigue
The source also notes reports of:
Heart palpitations
Insomnia
Fever
These latter effects warrant stopping and seeking appropriate medical evaluation rather than being assumed to be expected peptide effects.
CB4211 SAFETY CONTEXT
A related MOTS-c analog, CB4211, completed early Phase I clinical research and was reportedly generally well tolerated.
Again, CB4211 is not native MOTS-c, so these findings provide related context rather than definitive native MOTS-c safety data.
GLUCOSE & METABOLIC EFFECTS
Because MOTS-c is researched for glucose metabolism and AMPK signaling, theoretical interactions may exist with:
Insulin
Metformin
Other glucose-lowering agents
Human interaction studies are limited.
CANCER SIGNALING
Your Project source identifies mixed preclinical findings involving tumor biology.
Some research suggests inhibitory effects in certain tumor models, while other literature raises concerns in different cancer contexts.
Because the direction of effect is uncertain, active cancer or recent cancer history is an area requiring caution rather than assuming MOTS-c is anti-cancer or cancer-promoting.
PREGNANCY & BREASTFEEDING
There are insufficient human safety data to establish MOTS-c safety during pregnancy or lactation.
IMMUNOGENICITY
As with other peptide products, there is theoretical potential for immune reactions or antibody formation.
Human data are limited.
PRODUCT QUALITY
Research-grade peptide quality creates additional risks involving:
Incorrect identity
Incorrect concentration
Degradation
Impurities
Sterility failure
Lot-to-lot variation
A COA can characterize a specific tested sample but does not establish medical safety.
REGULATORY CONTEXT
MOTS-c IS NOT FDA APPROVED
MOTS-c is not an FDA-approved drug for any therapeutic indication.
There is no FDA-approved MOTS-c prescription product.
FDA COMPOUNDING HISTORY
Your Project profile documents that MOTS-c had previously appeared in FDA 503A Category 2, the category used for substances identified as raising significant safety concerns during review.
The source further notes that on April 22, 2026, MOTS-c was removed from Category 2 after the original nomination was withdrawn.
IMPORTANT REGULATORY DISTINCTION
Removal from Category 2 does not mean:
MOTS-c became FDA approved
FDA established that MOTS-c is safe
FDA established clinical effectiveness
MOTS-c was added to the 503A Bulks List
Your Project source specifically notes that MOTS-c had not been added to the 503A Bulks List at the time of that review.
PHARMACY COMPOUNDING REVIEW
The Project source also documents planned FDA Pharmacy Compounding Advisory Committee review of MOTS-c-related substances.
These proceedings concern compounding policy and do not constitute drug approval.
ANTI-DOPING STATUS
MOTS-c is prohibited under the World Anti-Doping Agency Prohibited List, where it is associated with AMPK activators and metabolic modulators.
Competitive athletes subject to anti-doping rules should not assume that research status makes MOTS-c permissible.
IMPORTANT REGULATORY DISTINCTION
Research status ≠ FDA approval
Removal from a compounding-risk category ≠ positive safety determination
Compounding review ≠ established clinical efficacy
ANALYTICAL DOCUMENTATION
Croix maintains available third party analytical documentation only for specific samples and lots that can be matched to corresponding laboratory reports.
MOTS-c 10 MG
Laboratory
Optiq Health Labs
Sample Name
mots c 10mg
Lot
kizen72826
Sample ID
1274.OPT.260910
Sample Matrix
Lyophilized Peptide
Intended Use
Research Use Only
Report Date
September 18, 2026
Reported Net Content
9.77 mg/vial
Reported Purity
99.7%
Identity
LC-MS Confirmation • MOTS-c Tested
Endotoxin
Pass • LAL ≤ 0.05 EU/mg
Sterility
Pass • USP <71> • No Growth COAs-2(2)
MOTS-c 20 MG
Laboratory
Optiq Health Labs
Sample Name
mots c 20mg
Lot
mt20260702
Sample ID
1278.OPT.260910
Sample Matrix
Lyophilized Peptide
Intended Use
Research Use Only
Report Date
September 18, 2026
Reported Net Content
19.67 mg/vial
Reported Purity
99.6%
Identity
LC-MS Confirmation • MOTS-c Tested
Endotoxin
Pass • LAL ≤ 0.05 EU/mg
Sterility
Pass • USP <71> • No Growth COAs-2(2)
IMPORTANT COA LIMITATION
Analytical results apply only to the specific samples identified in the corresponding laboratory reports.
A Certificate of Analysis for one sample does not establish the composition, purity, sterility, safety, efficacy, or characteristics of another sample, lot, batch, or product.
Croix requires the product, strength, lot or batch, sample ID, laboratory, and report date to be matched before analytical documentation is represented as supporting a product.
A passing COA does not establish FDA approval, clinical efficacy, medical suitability, or the characteristics of unrelated lots.
SELECTED RESEARCH & REFERENCES
Lee C, Zeng J, Drew BG, et al.
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.
Cell Metabolism. 2015.
Foundational preclinical metabolic research.
Reynolds JC, Lai RW, Woodhead JST, et al.
MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.
Nature Communications. 2021.
Preclinical and translational exercise/aging research.
Kumagai H, Coelho AR, Wan J, et al.
Research examining MOTS-c, myostatin, and muscle-atrophy signaling.
American Journal of Physiology – Endocrinology and Metabolism. 2021.
Wan W, Zhang L, Lin Y, et al.
Review of mitochondria-derived MOTS-c in stress, metabolism, and aging.
Journal of Translational Medicine. 2023.
Kong BS, Lee C, Cho YM.
Review of MOTS-c in mitochondrial-encoded peptide biology, diabetes, and aging-related disease.
Donin R, Pycha M, Nikoleli-Syrakou A, et al.
Human observational research examining circulating MOTS-c and lower-body muscle strength.
Wang Y, et al.
Research reviewing MOTS-c and bone metabolism.
Zhu W, Liu Y, Han P, et al.
Preclinical research examining MOTS-c in inflammatory pain biology.
Yin Y, Pan Y, He J, et al.
Research examining MOTS-c in ovarian-cancer models.
U.S. Anti-Doping Agency
MOTS-c peptide information.
World Anti-Doping Agency
Current Prohibited List covering MOTS-c under metabolic-modulator provisions.
U.S. Food & Drug Administration
503A bulk drug substance and compounding-related materials concerning MOTS-c.
EVIDENCE NOTE
MOTS-c has a substantial and biologically coherent preclinical literature involving metabolic regulation, AMPK signaling, exercise adaptation, glucose handling, and mitochondrial stress response.
Direct human evidence for native exogenous MOTS-c remains limited.
Evidence involving the related analog CB4211 should not be presented as though it were direct clinical evidence for native MOTS-c.
RESEARCH & EDUCATIONAL INFORMATION
This profile is provided for research and educational reference. It does not constitute individualized medical advice or establish MOTS-c as safe or effective for personal use.
MOTS-c is an investigational mitochondria-derived peptide studied primarily in metabolic, exercise, cellular-stress, and aging-related research.
MOTS-c is not FDA approved for any therapeutic indication.
Most evidence supporting effects on glucose handling, insulin sensitivity, physical performance, body composition, inflammation, or longevity comes from animal, laboratory, mechanistic, or observational research.
Human evidence for native exogenous MOTS-c remains limited, and findings from related analogs such as CB4211 should not be treated as direct proof of native MOTS-c safety or efficacy.
Analytical documentation presented by Croix applies only to the specific samples and lots identified in corresponding laboratory reports.